Hospira Inc (HSP.N)

HSP.N on New York Stock Exchange

51.84USD
28 Jul 2014
Price Change (% chg)

$0.12 (+0.23%)
Prev Close
$51.72
Open
$52.53
Day's High
$54.24
Day's Low
$51.74
Volume
495,812
Avg. Vol
238,682
52-wk High
$54.24
52-wk Low
$38.12

HSP.N

Chart for HSP.N

About

Hospira, Inc. (Hospira) is a provider of injectable drugs and infusion technologies. Hospira's portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Hospira conducts operations worldwide and is managed in three reportable segments: Americas;... (more)

Overall

Beta: 0.61
Market Cap (Mil.): $8,664.76
Shares Outstanding (Mil.): 167.14
Dividend: --
Yield (%): --

Financials

  HSP.N Industry Sector
P/E (TTM): 63.53 35.65 36.07
EPS (TTM): 0.82 -- --
ROI: 2.40 18.91 18.18
ROE: 4.48 19.67 19.05
Search Stocks

Danone in talks to sell medical nutrition unit to Hospira: FT

PARIS - French dairy group Danone is in talks to sell its medical nutrition business to U.S. group Hospira in a deal valuing the unit at about $5 billion, the Financial Times reported on Sunday, citing people familiar with the situation.

27 Jul 2014

UPDATE 1-Danone in talks to sell medical nutrition unit to Hospira - FT

PARIS, July 27 - French dairy group Danone is in talks to sell its medical nutrition business to U.S. group Hospira in a deal valuing the unit at about $5 billion, the Financial Times reported on Sunday, citing people familiar with the situation.

27 Jul 2014

Danone in talks to sell medical nutrition unit to Hospira - FT

PARIS, July 27 - French dairy group Danone is in talks to sell its medical nutrition business to U.S. group Hospira in a deal valuing the unit at about $5 billion, the Financial Times reported on Sunday, citing people familiar with the situation.

27 Jul 2014

Hospira wins UK case to overturn patents on Roche drug Herceptin

LONDON - Hospira has successfully overturned two patents on Roche's blockbuster breast cancer drug Herceptin in Britain, clearing the way for it to launch a cheaper copycat version in the country.

10 Apr 2014

UPDATE 1-Hospira wins UK case to overturn patents on Roche drug Herceptin

* Roche considering its next steps (Adds Roche and Hospira comment, patent details)

10 Apr 2014

Hospira wins UK case to overturn patents on Roche drug Herceptin

LONDON, April 10 - Hospira has successfully overturned two patents on Roche's top-selling breast cancer drug Herceptin in Britain, clearing the way for it to launch a cheaper copycat version in the country.

10 Apr 2014

Hospira agrees to $60 mln settlement over quality control problems

NEW YORK, March 27 - Hospira Inc has agreed to pay $60 million to resolve a class action lawsuit accusing the drug maker of misleading investors about quality control problems that undermined an initiative to improve the company's margins and operations.

27 Mar 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks